Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Phytocannabinoids, such as cannabidiol (CBD) and tetrahydrocannabinol (THC), are compounds found in the cannabis plant that interact with the body’s endocannabinoid system. There is scientific evidence suggesting that certain phytocannabinoids may influence the GABAergic system. GABA (gamma-aminobutyric acid) is the primary inhibitory neurotransmitter in the central nervous system, playing a key role in reducing neuronal excitability and regulating anxiety, stress, and muscle tone.

Research indicates that CBD, in particular, can modulate GABAergic transmission. For instance, studies have shown that CBD acts as a positive allosteric modulator at GABA_A receptors, enhancing the effects of GABA and thereby increasing inhibitory neurotransmission (Bakas et al., 2017, British Journal of Pharmacology). This mechanism is thought to contribute to CBD’s anxiolytic and anticonvulsant properties. Similarly, THC and other phytocannabinoids may indirectly influence GABA activity by interacting with cannabinoid receptors that modulate neurotransmitter release.

However, while preclinical studies and some clinical trials support the potential of phytocannabinoids to affect the GABAergic system, the evidence is still emerging and not yet conclusive for broad therapeutic applications. Most studies have focused on specific phytocannabinoids (mainly CBD), rather than unspecified phytocannabinoids as a group. Nonetheless, the current scientific literature provides a rationale for their use in supporting GABA-related body systems, particularly in the context of anxiety and seizure disorders.

More about Phytocannabinoid (unspecified)
More about GABA

Other ingredients that support GABA

Other body systems supported by Phytocannabinoid (unspecified)

Products containing Phytocannabinoid (unspecified)